DPP4 and type 2 diabetes mellitus: Experimental data indicate that these bacterial enzymes may reduce active incretin levels and are differentially inhibited by DPP4-targeting drugs, suggesting that the gut microbiome composition could modulate the efficacy of DPP4 inhibitors in T2DM management.81